<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681600</url>
  </required_header>
  <id_info>
    <org_study_id>MoroccanSS</org_study_id>
    <nct_id>NCT03681600</nct_id>
  </id_info>
  <brief_title>Observatory of the Quality of Surgical Procedures for Digestive Cancers</brief_title>
  <acronym>Obchir</acronym>
  <official_title>Observatory of the Quality of Surgical Procedures for Digestive Cancers: Pilot Project.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moroccan Society of Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherche sur le Cancer (IRC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>L'Ecole nationale supérieure d'informatique et d'analyse des systèmes (ENSIAS)(Mohammed V university in Rabat)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculté des sciences de Rabat (Mohammed V university in Rabat)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stratance Consulting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Moroccan Society of Surgery</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery for digestive cancers is managed according to quality standards, validated by the
      scientific community. Despite the diffusion of these standards through the benchmarks of good
      practice, the results of the surgery remain disparate.

      In many countries, this &quot;inequality of opportunity&quot; has justified the establishment of
      quality assurance systems to measure the results of surgery for one or more localizations of
      digestive cancer.

      These surgical audit experiments have shown a positive, rapid and cost-effective impact on
      complication rates, recurrence rates and overall survival even in the absence of
      interventional measures. The data collected also helped to improve the management of
      subgroups of patients usually excluded from clinical trials.

      In Morocco, the National Cancer Prevention and Control Plan provides for the establishment of
      a quality assurance system with the introduction of a system for monitoring and evaluating
      the care of patients. This pilot project is part of this framework, for the group of patients
      who are candidates for surgery for digestive cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>90-day Mortality rate</measure>
    <time_frame>90 days from surgery</time_frame>
    <description>Death within 90 days of surgical procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90-day Complication rate</measure>
    <time_frame>90 days from surgery</time_frame>
    <description>Defined with by Clavien-Dindo grade I to IV within90 days of surgical procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Overall survival</measure>
    <time_frame>from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year</time_frame>
    <description>Overall survival is defined as time from initiation to death of any cause within 3years of surgical procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year disease free survival</measure>
    <time_frame>from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>Disease free survival is defined as time from initiation to death of any cause within 3years of surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment decisions made within multidisciplinary team meeting / tumour board</measure>
    <time_frame>Prior to surgery</time_frame>
    <description>For every localization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging</measure>
    <time_frame>Prior to surgery</time_frame>
    <description>For every localization</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Digestive System Neoplasms</condition>
  <condition>Surgery</condition>
  <condition>Surgery--Complications</condition>
  <condition>Quality of Health Care</condition>
  <condition>Medical Audit</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients operated for digestive cancer from 1st January 2018 to December 2020 in 4 moroccan
        surgical departments
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients operated for a digestive cancer, proven or suspected, in a curative or
             palliative intent In elective situation: inclusion from surgery programming In
             emergent situation: inclusion no later than 72 hours after surgery

          -  Cancer proven or suspected in the following digestive tract: colon, appendix, anus,
             rectum, esophagus, stomach, eso-gastric junction, bile ducts, ampulla of Vater ,
             pancreas, duodenum, small intestine and liver.

          -  Patient willing and able to agree to participate in the study

        Exclusion Criteria:

          -  Patient whose surgical intervention is indicated for:

               -  a condition that is not a digestive tract cancer, including whether
                  retrospectively surgical exploration and / or histological examination reveals
                  digestive localization cancer

               -  proven or suspected cancer of non-digestive location

               -  a proven or suspected cancer of peritoneal localization

          -  Patient whose surgical intervention is indicated for a progressive disease or a local
             recurrence proven or suspected of a digestive localization cancer having already been
             the resected (with the exception of situations of iterative liver resection for liver
             metastasis hepatic and recovery of the tumor bed after the discovery of vesicular
             cancer on cholecystectomy specimen)

          -  Patients whose intervention is for diagnostic purposes without any curative or
             palliative intention

          -  Patients whose surgery is a liver transplant

          -  Patients whose surgical intervention is local destruction (radiofrequency, microwaves)
             exclusively by percutaneous approach (without laparotomy or laparoscopy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amine Benkabbou, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Moroccan Society of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raouf Mohsine, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>National institut of oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelmalek Hrora, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moroccan Society of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amine Souadka, Pr</last_name>
    <phone>+212 666953668</phone>
    <email>a.souadka@um5s.net.ma</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anass Majbar, Pr</last_name>
    <phone>+212 668846573</phone>
    <email>anass.majbar@um5s.net.ma</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institut of Oncology, Surgical oncology department</name>
      <address>
        <city>Rabat</city>
        <state>Please Enter The State Or Province</state>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amine Souadka, Pr</last_name>
      <phone>666953668</phone>
      <email>a.souadka@um5s.net.ma</email>
    </contact>
    <contact_backup>
      <last_name>Amine Benkabbou, Pr</last_name>
      <email>a.benkabbou@um5s.net.ma</email>
    </contact_backup>
    <investigator>
      <last_name>Raouf Mohsine, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional center of oncology, surgical department</name>
      <address>
        <city>Oujda</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>El Harroudi Tijani, Pr</last_name>
      <email>el.harroudi@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Serji Badr, Pr</last_name>
      <email>badr.serji@hotmail.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Tijani El Harroudi, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ibn Sina Hospital, Surgical department A</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelkader Belkouchi, Pr</last_name>
      <email>belkouchiabdelkader@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Amine Benkabbou, Pr</last_name>
      <email>a.benkabbou@um5s.net.ma</email>
    </contact_backup>
    <investigator>
      <last_name>Abdelkader Belkouchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ibn Sina Hospital, Surgical department C</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Ahallat, Pr</last_name>
      <email>ahallat@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abdelmalek Hrora, Pr</last_name>
      <email>hroramalek@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammed Ahallat, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Morocco</country>
  </location_countries>
  <link>
    <url>https://sites.google.com/um5s.net.ma/observatoire</url>
    <description>Website of the project</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>audit</keyword>
  <keyword>cancer</keyword>
  <keyword>guidelines</keyword>
  <keyword>ouctomes</keyword>
  <keyword>survival</keyword>
  <keyword>digestive cancer surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

